Advertisement

Differentiation of Human B-Cell Tumors: A Preclinical Model for Differentiation Therapy

  • Ayad M. Al-Katib
  • Ramzi Mohammad
Part of the Developments in Oncology book series (DION, volume 77)

Abstract

B cell tumors in man include a group of heterogenous diseases with varying natural histories and responsiveness to therapy. Classic examples of B cell tumors are the chronic lymphocytic leukemia (CLL), Burkitt’s lymphoma and multiple myeloma. These tumors express the conventional B cell marker, that is, surface and/or cytoplasmic immunoglobulins. Malignant transformation, however, can affect precursors of the “mature” B lymphocytes as exemplified by the non-T cell acute lymphoblastic leukemia (ALL). Such cases demonstrate immunoglobulin gene rearrangements and react with monoclonal antibodies to B cell differentiation antigens. B cell tumors, therefore, represent a spectrum of disorders extending from the immature “stem cell” to the most mature “plasma cell” of the B lineage. It has been long hypothesized that disturbance in the differentiation pathway is important in the pathophysiology of malignancy (1). Phenotypic analysis of the B cell lineage has identified a malignant counterpart phenotype for each stage of the normal B cell differentiation pathway (3).

Keywords

Chronic Lymphocytic Leukemia Phorbol Ester Chronic Lymphocytic Leukemia Cell Hairy Cell Severe Combine Immune Deficient Mouse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Market CL: Neoplasia: A disease of cell differentiation. Cancer Res. 28:1908–1914, 1968.Google Scholar
  2. 2.
    Sachs L: Cell differentiation by bypassing of genetic defects in the suppression of malignancy. Cancer Res 47:1981–1986, 1987.PubMedGoogle Scholar
  3. 3.
    Anderson KC, Bates MP, Slaughehoupt BL, et al: Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 63:1424–1433, 1984.PubMedGoogle Scholar
  4. 4.
    Hashimi L, Wang CY, Al-Katib A, Koziner B: Cellular distribution of a Bcell specific surface antigen (gp 54) detected by a monoclonal antibody (anti-BL4). Cancer Res. 46:5431–5437, 1986.PubMedGoogle Scholar
  5. 5.
    Hokland P, Ritz J, Schlossman SF, Nadler LM: Orderly expression of B cell antigens during the in vitro differentiation of non-malignant human Pre-B cells. J. Immunol. 135:1746–1751, 1985.PubMedGoogle Scholar
  6. 6.
    Loken M, Shah VO, Dattilio KL, Civin CI: Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. Blood 70:1316–1324, 1987.PubMedGoogle Scholar
  7. 7.
    Wang CY, Azzo W, Al-Katib A, et al: Preparation and characterization of monoclonal antibodies recognizing three distinct differentiation antigens (Bill/ BL2, BL3) on human B lymphocytes. J. Immunol. 133:684–691, 1984.PubMedGoogle Scholar
  8. 8.
    Al-Katib A, Wang CY, Bardales R, Koziner B: Phenotypic characterization on Non-T, Non-B acute lymphoblastic leukemia by a new panel (BL) of monoclonal antibodies. Hematol. Oncol. 3:271–281, 1985.PubMedCrossRefGoogle Scholar
  9. 9.
    Small TN, Keever CA, Weiner-Fedus S, et al: B-cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: A recapitulation of normal B-cell ontogeny. Blood 76:1647–1656, 1990.PubMedGoogle Scholar
  10. 10.
    Al-Katib A, Koziner B: Leu-10 (HLA-DC/DS) antigen distribution in human leukaemic disorders as detected by a monoclonal antibody: Correlation with HLA-DR expression. Br. J. Haematol. 57:373–382, 1984.PubMedCrossRefGoogle Scholar
  11. 11.
    Wang CY, Al-Katib A, Lane CL, et al: Induction of HLA-DC/DS (LeulO) antigen expression by human precursor B cell lines. J. Exp. Med. 158:1757–1762, 1983.PubMedCrossRefGoogle Scholar
  12. 12.
    Cossman J, Neckers LM, Arnold A, Korsmeyer SJ: Induction of differentiation in a case of common acute lymphoblastic leukemia. New Engl. J. Med. 307:1251–1254, 1982.PubMedCrossRefGoogle Scholar
  13. 13.
    Sugawara I: The immunoglobulin production of human peripheral B lymphocytes induced by phorbol myristate acetate. Cellular Immunol. 72:88–96, 1982.CrossRefGoogle Scholar
  14. 14.
    Efremidis AP, Haubenstock H, Holland JF, Bekesi JG: TPA-induced maturation in secretory human B-leukemic cells in vitro: DNA synthesis, antigenic changes, and immunoglobulin secretion. Blood 66:953–960, 1985.PubMedGoogle Scholar
  15. 15.
    Nadler LM, Anderson KC, Marti G, et al: B4, a human lymphocyte associated antigen expressed on normal, mitogen activated and malignant B lymphocytes. J. Immunol. 131:244–250, 1983.PubMedGoogle Scholar
  16. 16.
    Janossy G, Bollum FJ, Bradstock KF, et al: Terminal transferase positive bone marrow cells exhibit the antigen phenotype of common acute lymphoblastic leukemia. J. Immunol. 123:1525–1530, 1979.PubMedGoogle Scholar
  17. 17.
    Patel B, Mohammad RM, Blaustein J, Al-Katib A: Induced expression of a monocytoid B lymphocyte antigen phenotype on the Reh cell line. Am. J. Hematol. 33:153–159, 1990.PubMedCrossRefGoogle Scholar
  18. 18.
    Liendo C, Danieu L, Al-Katib A, Koziner B: Phenotypic analysis by flow cytometry of surface immunoglobulin light chains and B and T cell antigens in lymph nodes involved with non-Hodgkin’s lymphoma. Am. J. Med. 79:445–454, 1985.PubMedCrossRefGoogle Scholar
  19. 19.
    Vogler LB, Crist WM, Bookman DE, et al: Pre-B-cell leukemia: A new phenotype of childhood lymphoblastic leukemia. N. Engl. J. Med. 298:872–878, 1978.PubMedCrossRefGoogle Scholar
  20. 20.
    Nadler LM, Stashenko P, Hardy R, et al: Characterization of a human B cell specific antigen (B2) distinct from Bl. J. Immunol. 126:1941–1947, 1981.PubMedGoogle Scholar
  21. 21.
    Al-Katib A, Wang CY, Koziner B: Distribution of a new B-cell associated surface antigen (BL7) detected by a monoclonal antibody in human leukemic disorders. Cancer Res. 45:3058–3063, 1985.PubMedGoogle Scholar
  22. 22.
    Schwarting R, Stein H, Wang CY: The monoclonal antibodies α S-HCL1 (α Leu-14) and α S-HCL3 (α Leu-M5) allow the diagnosis of hairy cell leukemia. Blood 65:974–983, 1985.PubMedGoogle Scholar
  23. 23.
    Sheibani K, Burke JS, Swartz WG, et al: Monocytoid B-cell lymphoma: Clinico-pathologic study of 21 cases of a unique type of low-grade lymphoma. Cancer 62:1531–1538, 1988.PubMedCrossRefGoogle Scholar
  24. 24.
    Traweek ST, Sheibani K, Winberg CD, et al: Monocytoid B-cell lymphoma: Its evaluation and relationship to other low-grade B-cell neoplasms. Blood 73:573–578, 1989.PubMedGoogle Scholar
  25. 25.
    Burke JS, Sheibani K: Hairy cells and monocytoid B lymphocytes: Are they related? Leukemia 1:298–300, 1987.PubMedGoogle Scholar
  26. 26.
    Anderson KC, Park EK, Bates MP, et al: Antigens on human plasma cells identified by monoclonal antibodies. J. Immunol. 130:1132–1138, 1983.PubMedGoogle Scholar
  27. 27.
    Anderson KC, Bates MP, Slaughenhoupt B, et al: A monoclonal antibody with reactivity restricted to normal and neoplastic plasma cells. J. Immunol. 132:3172–3179, 1984.PubMedGoogle Scholar
  28. 28.
    Finerty S, Rickinson AB, Epstein MA, Platts-Mills TAE: Interaction of Epstein-Barr virus with leukemic B cells in vitro. II. Cell line establishment from prolymphocytic leukemia and from Waldenstrom’s macroglobulinemia. Int. J. Cancer 30:1–7, 1982.PubMedCrossRefGoogle Scholar
  29. 29.
    Mohamed AN, Al-Katib A: Establishment and characterization of a human lymphoma cell line (WSU-NHL) with 14;18 translocation. Leuk. Res. 12:833–843, 1988.PubMedCrossRefGoogle Scholar
  30. 30.
    Mohamed AN, Mohammad RM, Koop BI, Al-Katib A: Establishment and characterization of a new human Burkitt lymphoma cell line (WSU-BL). Cancer 64: 1041–1048, 1989.PubMedCrossRefGoogle Scholar
  31. 31.
    Mohammad RM, Mohamed AN, KuKuruga M, et al: A human B-cell lymphoma line with de novo multidrug resistance phenotype. Cancer 69:1468–1474, 1992.PubMedCrossRefGoogle Scholar
  32. 32.
    Al-Katib A, Mohammad R, Hamdan M, et al: Propagation of Waldenstrom’s macroglobulinemia cells in vitro and in severe combined immune deficient mice: Utility as a preclinical drug screening model. Blood 81:3034–3042, 1993.PubMedGoogle Scholar
  33. 33.
    Mohammad RM, Smith MR, Mohamed AN, Al-Katib A: A unique EBV-negative low grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8,ll) chromosomal translocations. Cancer Genet. Cytogenet. 70:62–67, 1993.PubMedCrossRefGoogle Scholar
  34. Hamdan M, Mohammad RM, Mohamed A, Al-Katib A: Development of a xenograft model for diffuse large cell human lymphoma (DLCL) in SCID mice. Proc., AACR, abst #349, 1993.Google Scholar
  35. 35.
    Rosenberg SA, Bernard CW, Brown BW Jr, et al: National Cancer Institute sponsored study of classification of non-Hodgkin’s lymphomas: Summary and description of working formulation for clinical usage. Cancer 49:2112–2135, 1982.CrossRefGoogle Scholar
  36. 36.
    Totterman TH, Nilsson K, Sundstrom C: Phorbol ester-induced differentiation of chronic lymphocytic leukemia cells. Nature 288:176–178, 1980.PubMedCrossRefGoogle Scholar
  37. 37.
    Al-Katib A, Wang CY, McKenzie S, et al: Phorbol ester-induced hairy cell features on chronic lymphocytic leukemia cells in vitro. Am. J. Hematol. 40:264–269, 1992.PubMedCrossRefGoogle Scholar
  38. 38.
    Mohamed AN, Nakeff A, Mohammad RM, et al: Modulation of c-myc oncogene expression by phorbol ester and interferon-gamma: Appraisal by flow cytometry. Oncogene 3:429–435, 1988.PubMedGoogle Scholar
  39. 39.
    Al-Katib A, Mohammad RM, Mohamed AN, et al: Conversion of high grade lymphoma tumor cell line to intermediate grade with TPA and bryostatin 1 as determined by polypeptide analysis on 2D gel electrophoresis. Hematol. Oncol. 8:81–89, 1990.PubMedCrossRefGoogle Scholar
  40. 40.
    Pettit GR, Day JF, Hartwell JL, Wood HB: Antineoplastic components of marine animals. Nature 227: 962–963, 1970.PubMedCrossRefGoogle Scholar
  41. 41.
    Pettit GR, Herald SL, Doubek DL, et al: Isolation and structure of bryostatin 1. J. Am. Chem. Soc. 104:6846–6848, 1982.CrossRefGoogle Scholar
  42. 42.
    Hennings H, Blumberg PM, Pettit GR, et al: Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol ester in SENCAR mouse skin. Carcinogenesis 8:1343–1346, 1987.PubMedCrossRefGoogle Scholar
  43. 43.
    Al-Katib A, Mohammad RM, Khan K, et al: Bryostatin 1-induced modulation of the acute lymphoblastic leukemia cell line Reh. J. Immunother. 14:33–42, 1993.CrossRefGoogle Scholar
  44. 44.
    Mohammad RM, Al-Katib A, Pettit GR, Sensenbrenner LL: Differential effects of bryostatin 1 on human non-Hodgkin’s lymphoma cell lines. Leuk. Res. 17:1–8, 1993.PubMedCrossRefGoogle Scholar
  45. 45.
    Al-Katib A, Mohammad RM, Dan M, et al: Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro. Exp. Hematol. 21:61–65, 1993.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Ayad M. Al-Katib
  • Ramzi Mohammad

There are no affiliations available

Personalised recommendations